Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

https://m2.mtmt.hu/ hun 2026-05-31 03:54 JournalArticle 34724783 VALIDATED true 0 false 2026-05-23T15:02:53.604+0000 2025-05-16T11:10:26.728+0000 2024-03-07T07:33:26.596+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2026-03-27T10:20:50.737+0000 2026-03-27T10:20:50.737+0000 2025-05-16T11:10:28.516+0000 true 10062062 Gere Tamásné /api/admin/10062062 Admin Gere Tamásné (SE_KK_Admin5_GT, admin) true 10062062 Admin 10025544 /api/admin/10025544 Lévayné Deseő Katalin (MTMT Központi admin) Lévayné Deseő Katalin true 10025544 true 2025-06-04T23:11:58.550+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Sayour, Nabil V Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence true true /api/journal/1482 REVIEWED EUROPEAN HEART JOURNAL 0195-668X 1522-9645 true false 1482 false 1482 true 0195-668X 1522-9645 Journal FOREIGN 45 14 1224 1240 1224 17 2024 Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided. Funding 2038833 /api/funding/2038833 Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL(739593) Támogató: Horizon 2020 false true Funding 2038834 /api/funding/2038834 (LP-2021-38) Támogató: Hungarian Academy of Sciences false true Funding 2038835 /api/funding/2038835 National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751) false true Funding 2038836 /api/funding/2038836 (2020-4.1.1.-TKP2020) false true Funding 2038837 /api/funding/2038837 (2020-1.1.5-GYORSÍTÓSÁV-2021-00011) false true Funding 2038838 /api/funding/2038838 (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium false true Funding 2038839 /api/funding/2038839 (TKP/ITM/NKFIH) false true Funding 2038840 /api/funding/2038840 Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH false true Funding 2038841 /api/funding/2038841 Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP false true true 2024 true true true false true false GOLD 2026-05-23 true https://doi.org/10.1093/eurheartj/ehae105 33 0 33 22 4 32 33 33 31 33 33 22 22 22 11 0 33 22 33 22 0 10 10 Folyóiratcikk Journal Article 24 33 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 7 6 7 6 2025 0 21 12 21 12 2026 0 5 4 5 4 D1 false 10028393 false false false 2024-04-07T08:43:40.579+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 4 21 4 20 0 true 10025544 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 115613596 /api/authorship/115613596 Sayour, Nabil V [Sayour, Viktor Nabil (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI) 1 0.05 true false false Author 10074459 /api/author/10074459 Sayour Viktor Nabil (farmakológia) Sayour Viktor Nabil true true Sayour Nabil V true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613597 /api/authorship/115613597 Paál, Ágnes M [Paál, Ágnes (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 2 0.05 false false false Author 10077413 /api/author/10077413 Paál Ágnes (farmakológia) Paál Ágnes true true Paál Ágnes M true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613598 /api/authorship/115613598 Ameri, Pietro 3 0.05 false false false Ameri Pietro true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613599 /api/authorship/115613599 Meijers, Wouter C 4 0.05 false false false Meijers Wouter C true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613600 /api/authorship/115613600 Minotti, Giorgio 5 0.05 false false false Minotti Giorgio true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613601 /api/authorship/115613601 Andreadou, Ioanna 6 0.05 false false false Andreadou Ioanna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613602 /api/authorship/115613602 Lombardo, Antonella 7 0.05 false false false Lombardo Antonella true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613603 /api/authorship/115613603 Camilli, Massimiliano 8 0.05 false false false Camilli Massimiliano true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613604 /api/authorship/115613604 Drexel, Heinz 9 0.05 false false false Drexel Heinz true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613605 /api/authorship/115613605 Grove, Erik Lerkevang 10 0.05 false false false Grove Erik Lerkevang true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613606 /api/authorship/115613606 Dan, Gheorghe Andrei 11 0.05 false false false Dan Gheorghe Andrei true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613607 /api/authorship/115613607 Ivanescu, Andreea 12 0.05 false false false Ivanescu Andreea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613608 /api/authorship/115613608 Semb, Anne Grete 13 0.05 false false false Semb Anne Grete true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613609 /api/authorship/115613609 Savarese, Gianluigi 14 0.05 false false false Savarese Gianluigi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613610 /api/authorship/115613610 Dobrev, Dobromir 15 0.05 false false false Dobrev Dobromir true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613611 /api/authorship/115613611 Crea, Filippo 16 0.05 false false false Crea Filippo true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613612 /api/authorship/115613612 Kaski, Juan-Carlos 17 0.05 false false false Kaski Juan-Carlos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613613 /api/authorship/115613613 de Boer, Rudolf A 18 0.05 false false false de Boer Rudolf A true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613614 /api/authorship/115613614 Ferdinandy, Péter** [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI) 19 0.05 false true false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115613615 /api/authorship/115613615 Varga, Zoltán V ✉ [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI) 20 0.05 false true true Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 25833611 /api/publicationidentifier/25833611 DOI: 10.1093/eurheartj/ehae105 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1093/eurheartj/ehae105 https://doi.org/10.1093/eurheartj/ehae105 false true PublicationIdentifier 25936362 /api/publicationidentifier/25936362 WoS: 001178569200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001178569200001 https://www.webofscience.com/wos/woscc/full-record/001178569200001 true true PublicationIdentifier 26001362 /api/publicationidentifier/26001362 Scopus: 85188432275 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85188432275 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85188432275 false true PublicationIdentifier 25833612 /api/publicationidentifier/25833612 PubMed: 38441940 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38441940 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38441940&dopt=Abstract false true SjrRating 11446414 /api/sjrrating/11446414 sjr:D1 (2024) Scopus - Cardiology and Cardiovascular Medicine EUROPEAN HEART JOURNAL 0195-668X 1522-9645 8 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2705 /api/classificationexternal/2705 Scopus - Cardiology and Cardiovascular Medicine true 2705 true D1 DIRECT true true Reference 50771182 /api/reference/50771182 1. McDonagh 2021: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure., Eur Heart J, 42, p. 3599, DOI: 10.1093/eurheartj/ehab368 1 10.1093/eurheartj/ehab368 false true Reference 50771183 /api/reference/50771183 2. Heidenreich 2022: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines., J Am Coll Cardiol, 79, p. e263, DOI: 10.1016/j.jacc.2021.12.012 2 10.1016/j.jacc.2021.12.012 false true Reference 50771184 /api/reference/50771184 3. Lyon 2022: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS): developed by the T., Eur Heart J, 43, p. 4229, DOI: 10.1093/eurheartj/ehac244 3 10.1093/eurheartj/ehac244 false true Reference 50771185 /api/reference/50771185 4. James 2018: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017., Lancet, 392, p. 1789, DOI: 10.1016/S0140-6736(18)32279-7 4 10.1016/S0140-6736(18)32279-7 false true Reference 50771186 /api/reference/50771186 5. Savarese 2022: Global burden of heart failure: a comprehensive and updated review of epidemiology., Cardiovasc Res, 118, p. 3272, DOI: 10.1093/cvr/cvac013 5 10.1093/cvr/cvac013 false true Reference 50771187 /api/reference/50771187 6. Sung 2021: Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA Cancer J Clin, 71, p. 209, DOI: 10.3322/caac.21660 6 10.3322/caac.21660 false true Reference 50771188 /api/reference/50771188 7. Aboumsallem 2020: Reverse cardio-oncology: cancer development in patients with cardiovascular disease., J Am Heart Assoc, 9, p. e013754, DOI: 10.1161/JAHA.119.013754 7 10.1161/JAHA.119.013754 false true Reference 50771189 /api/reference/50771189 8. de Boer 2020: Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the translational research committee of the heart failure association (HFA) of the European society of cardiology (ESC)., Eur J Heart Fail, 22, p. 2272, DOI: 10.1002/ejhf.2029 8 10.1002/ejhf.2029 false true Reference 50771190 /api/reference/50771190 9. Bertero 2018: Linking heart failure to cancer., Circulation, 138, p. 735, DOI: 10.1161/CIRCULATIONAHA.118.033603 9 10.1161/CIRCULATIONAHA.118.033603 false true Reference 50771191 /api/reference/50771191 10. Lau 2021: Cardiovascular risk factors are associated with future cancer., JACC Cardio Oncol, 3, p. 48, DOI: 10.1016/j.jaccao.2020.12.003 10 10.1016/j.jaccao.2020.12.003 false true Reference 50771192 /api/reference/50771192 11. Narayan 2020: Mechanistic biomarkers informative of both cancer and cardiovascular disease: jACC state-of-the-art review., J Am Coll Cardiol, 75, p. 2726, DOI: 10.1016/j.jacc.2020.03.067 11 10.1016/j.jacc.2020.03.067 false true Reference 50771193 /api/reference/50771193 12. Sturgeon 2019: A population-based study of cardiovascular disease mortality risk in US cancer patients., Eur Heart J, 40, p. 3889, DOI: 10.1093/eurheartj/ehz766 12 10.1093/eurheartj/ehz766 false true Reference 50771194 /api/reference/50771194 13. Zaorsky 2017: Causes of death among cancer patients., Ann Oncol, 28, p. 400, DOI: 10.1093/annonc/mdw604 13 10.1093/annonc/mdw604 false true Reference 50771195 /api/reference/50771195 14. Mehta 2018: Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American heart association., Circulation, 137, p. e30, DOI: 10.1161/CIR.0000000000000556 14 10.1161/CIR.0000000000000556 false true Reference 50771196 /api/reference/50771196 15. Zamorano 2020: The cancer patient and cardiology., Eur J Heart Fail, 22, p. 2290, DOI: 10.1002/ejhf.1985 15 10.1002/ejhf.1985 false true Reference 50771197 /api/reference/50771197 16. Tocchetti 2020: Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart., Cardiovasc Res, 116, p. 1820, DOI: 10.1093/cvr/cvaa222 16 10.1093/cvr/cvaa222 false true Reference 50771198 /api/reference/50771198 17. Efentakis 2022: Myocardial protection and current cancer therapy: two opposite targets with inevitable cost., Int J Mol Sci, 23, p. 14121, DOI: 10.3390/ijms232214121 17 10.3390/ijms232214121 false true Reference 50771199 /api/reference/50771199 18. Gergely 2023: Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment., Br J Pharmacol, 180, p. 740, DOI: 10.1111/bph.15984 18 10.1111/bph.15984 false true Reference 50771200 /api/reference/50771200 19. Banke 2016: Incidence of cancer in patients with chronic heart failure: a long-term follow-up study., Eur J Heart Fail, 18, p. 260, DOI: 10.1002/ejhf.472 19 10.1002/ejhf.472 false true Reference 50771201 /api/reference/50771201 20. Hasin 2016: Heart failure after myocardial infarction is associated with increased risk of cancer., J Am Coll Cardiol, 68, p. 265, DOI: 10.1016/j.jacc.2016.04.053 20 10.1016/j.jacc.2016.04.053 false true Reference 50771202 /api/reference/50771202 21. Battisti 2022: Prevalence of cardiovascular disease in patients with potentially curable malignancies., JACC Cardio Oncol, 4, p. 238, DOI: 10.1016/j.jaccao.2022.03.004 21 10.1016/j.jaccao.2022.03.004 false true Reference 50771203 /api/reference/50771203 22. Leedy 2021: The association between heart failure and incident cancer in women: an analysis of the women’s health initiative., Eur J Heart Fail, 23, p. 1712, DOI: 10.1002/ejhf.2207 22 10.1002/ejhf.2207 false true Reference 50771204 /api/reference/50771204 23. Roderburg 2021: Heart failure is associated with an increased incidence of cancer diagnoses., ESC Hear. Fail, 8, p. 3628, DOI: 10.1002/ehf2.13421 23 10.1002/ehf2.13421 false true Reference 50771205 /api/reference/50771205 24. Edoardo 2022: Cancer incidence and mortality according to Pre-existing heart failure in a community-based cohort., JACC CardioOncol, 4, p. 98, DOI: 10.1016/j.jaccao.2021.11.007 24 10.1016/j.jaccao.2021.11.007 false true Reference 50771206 /api/reference/50771206 25. Camilli 2023: Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis., Cardio-Oncol, 9, p. 8, DOI: 10.1186/s40959-023-00158-1 25 10.1186/s40959-023-00158-1 false true Reference 50771207 /api/reference/50771207 26. Selvaraj 2018: Lack of association between heart failure and incident cancer., J Am Coll Cardiol, 71, p. 1501, DOI: 10.1016/j.jacc.2018.01.069 26 10.1016/j.jacc.2018.01.069 false true Reference 50771208 /api/reference/50771208 27. Schwartz 2020: Prevalence and incidence of Various cancer subtypes in patients with heart failure vs matched controls., Int J Cardiol, 316, p. 209, DOI: 10.1016/j.ijcard.2020.05.035 27 10.1016/j.ijcard.2020.05.035 false true Reference 50771209 /api/reference/50771209 28. Bruhn 2023: Temporal trends in the incidence of malignancy in heart failure: a nationwide danish study., Eur Heart J, 44, p. 1124, DOI: 10.1093/eurheartj/ehac797 28 10.1093/eurheartj/ehac797 false true Reference 50771210 /api/reference/50771210 29. Ameri 2023: Cancer is a comorbidity of heart failure., Eur Heart J, 44, p. 1133, DOI: 10.1093/eurheartj/ehac710 29 10.1093/eurheartj/ehac710 false true Reference 50771211 /api/reference/50771211 30. Cole 2012: Molecular pathways: beta-adrenergic signaling in cancer., Clin Cancer Res, 18, p. 1201, DOI: 10.1158/1078-0432.CCR-11-0641 30 10.1158/1078-0432.CCR-11-0641 false true Reference 50771212 /api/reference/50771212 31. Sloan 2010: The sympathetic nervous system induces a metastatic switch in primary breast cancer., Cancer Res, 70, p. 7042, DOI: 10.1158/0008-5472.CAN-10-0522 31 10.1158/0008-5472.CAN-10-0522 false true Reference 50771213 /api/reference/50771213 32. Zhou 2016: Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway., Oncotarget, 7, p. 68314, DOI: 10.18632/oncotarget.11599 32 10.18632/oncotarget.11599 false true Reference 50771214 /api/reference/50771214 33. Partecke 2016: Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by Beta-adrenergic receptor blockade., Pancreatology, 16, p. 423, DOI: 10.1016/j.pan.2016.03.005 33 10.1016/j.pan.2016.03.005 false true Reference 50771215 /api/reference/50771215 34. Wei 2016: Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib., Oncol Rep, 36, p. 1576, DOI: 10.3892/or.2016.4918 34 10.3892/or.2016.4918 false true Reference 50771216 /api/reference/50771216 35. Maccari 2017: Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice., Br J Pharmacol, 174, p. 139, DOI: 10.1111/bph.13662 35 10.1111/bph.13662 false true Reference 50771217 /api/reference/50771217 36. Wrobel 2015: Inhibition of human melanoma growth by a non-cardioselective β-blocker., J Invest Dermatol, 135, p. 525, DOI: 10.1038/jid.2014.373 36 10.1038/jid.2014.373 false true Reference 50771218 /api/reference/50771218 37. Sorski 2016: Reducing liver metastases of colon cancer in the context of extensive and Minor surgeries through β-adrenoceptors blockade and COX2 inhibition., Brain Behav Immun, 58, p. 91, DOI: 10.1016/j.bbi.2016.05.017 37 10.1016/j.bbi.2016.05.017 false true Reference 50771219 /api/reference/50771219 38. Kuang 2018: Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma., Oncotarget, 9, p. 802, DOI: 10.18632/oncotarget.22696 38 10.18632/oncotarget.22696 false true Reference 50771220 /api/reference/50771220 39. Pasquier 2013: β-Blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma., Br J Cancer, 108, p. 2485, DOI: 10.1038/bjc.2013.205 39 10.1038/bjc.2013.205 false true Reference 50771221 /api/reference/50771221 40. Palm 2006: The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers., Int J Cancer, 118, p. 2744, DOI: 10.1002/ijc.21723 40 10.1002/ijc.21723 false true Reference 50771222 /api/reference/50771222 41. Kokolus 2018: Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice., Oncoimmunology, 7, p. e1405205, DOI: 10.1080/2162402X.2017.1405205 41 10.1080/2162402X.2017.1405205 false true Reference 50771223 /api/reference/50771223 42. Fjæstad 2022: Blockade of Beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment., Oncogene, 41, p. 1364, DOI: 10.1038/s41388-021-02170-0 42 10.1038/s41388-021-02170-0 false true Reference 50771224 /api/reference/50771224 43. Moisan 2021: Critical role of aquaporin-1 and telocytes in infantile hemangioma response to propranolol Beta blockade., Proc Natl Acad Sci USA, 118, DOI: 10.1073/pnas.2018690118 43 10.1073/pnas.2018690118 false true Reference 50771225 /api/reference/50771225 44. MacDonald 2019: Adrenergic receptor signaling regulates the response of tumors to ionizing radiation., Radiat Res, 191, p. 585, DOI: 10.1667/RR15193.1 44 10.1667/RR15193.1 false true Reference 50771226 /api/reference/50771226 45. Acheampong 2021: Zanthoxylum Zanthoxyloides alkaloidal extract improves CCl4-induced hepatocellular carcinoma-like phenotypes in rats., Evid. Based. Complement. Altern. Med, 2021, p. 3804379, DOI: 10.1155/2021/3804379 45 10.1155/2021/3804379 false true Reference 50771227 /api/reference/50771227 46. Balaha 2016: Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats., Toxicol Appl Pharmacol, 311, p. 1, DOI: 10.1016/j.taap.2016.10.012 46 10.1016/j.taap.2016.10.012 false true Reference 50771228 /api/reference/50771228 47. Cleveland 2018: Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention., Mol Carcinog, 57, p. 997, DOI: 10.1002/mc.22820 47 10.1002/mc.22820 false true Reference 50771229 /api/reference/50771229 48. Gillis 2021: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients., Eur J Cancer, 147, p. 106, DOI: 10.1016/j.ejca.2021.01.029 48 10.1016/j.ejca.2021.01.029 false true Reference 50771230 /api/reference/50771230 49. Abdullah Shamim 2022: Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption., Int J Pharm, 611, p. 121302, DOI: 10.1016/j.ijpharm.2021.121302 49 10.1016/j.ijpharm.2021.121302 false true Reference 50771231 /api/reference/50771231 50. Chang 2015: Prevention of skin carcinogenesis by the β-blocker carvedilol., Cancer Prev Res, 8, p. 27, DOI: 10.1158/1940-6207.CAPR-14-0193 50 10.1158/1940-6207.CAPR-14-0193 false true Reference 50771232 /api/reference/50771232 51. Hoare 2022: Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy., Commun Biol, 5, p. 106, DOI: 10.1038/s42003-022-03041-4 51 10.1038/s42003-022-03041-4 false true Reference 50771233 /api/reference/50771233 52. Huang 2017: Topically applied carvedilol attenuates solar ultraviolet radiation induced skin carcinogenesis., Cancer Prev. Res, 10, p. 598, DOI: 10.1158/1940-6207.CAPR-17-0132 52 10.1158/1940-6207.CAPR-17-0132 false true Reference 50771234 /api/reference/50771234 53. Chen 2021: Adrenergic blockade by nebivolol to suppress oral squamous cell carcinoma growth via endoplasmic Reticulum stress and mitochondria dysfunction., Front Pharmacol, 12, p. 691998, DOI: 10.3389/fphar.2021.691998 53 10.3389/fphar.2021.691998 false true Reference 50771235 /api/reference/50771235 54. Niu 2021: FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth., Nat Commun, 12, p. 5919, DOI: 10.1038/s41467-021-26222-x 54 10.1038/s41467-021-26222-x false true Reference 50771236 /api/reference/50771236 55. Zhang 2010: Β2-Adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-ΚB and AP-1., Cancer Biol Ther, 10, p. 19, DOI: 10.4161/cbt.10.1.11944 55 10.4161/cbt.10.1.11944 false true Reference 50771237 /api/reference/50771237 56. Xie 2019: Β-blockers inhibit the viability of breast cancer cells by regulating the ERK/COX-2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms., Oncol Rep, 41, p. 341 56 false true Reference 50771238 /api/reference/50771238 57. Szewczyk 2012: A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer., Anticancer Res, 32, p. 2133 57 false true Reference 50771239 /api/reference/50771239 58. Koh 2021: Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis., Gastric Cancer, 24, p. 1037, DOI: 10.1007/s10120-021-01184-7 58 10.1007/s10120-021-01184-7 false true Reference 50771240 /api/reference/50771240 59. Sidorova 2022: The effect of Beta adrenoreceptor blockers on viability and cell colony formation of non-small cell lung cancer cell lines A549 and H1299., Molecules, 27, p. 1938, DOI: 10.3390/molecules27061938 59 10.3390/molecules27061938 false true Reference 50771241 /api/reference/50771241 60. Farhoumand 2022: The adrenergic receptor antagonist carvedilol elicits anti-tumor responses in uveal melanoma 3D tumor spheroids and may serve as co-adjuvant therapy with radiation., Cancers (Basel), 14, p. 3097, DOI: 10.3390/cancers14133097 60 10.3390/cancers14133097 false true Reference 50771242 /api/reference/50771242 61. Duckett 2020: The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells., Vet Comp Oncol, 18, p. 128, DOI: 10.1111/vco.12560 61 10.1111/vco.12560 false true Reference 50771243 /api/reference/50771243 62. Zhang 2009: Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of Beta-adrenoceptor antagonist’s anticancer effect in pancreatic cancer cell., Pancreas, 38, p. 94, DOI: 10.1097/MPA.0b013e318184f50c 62 10.1097/MPA.0b013e318184f50c false true Reference 50771244 /api/reference/50771244 63. Negro 2006: Erbb2 is required for G protein-coupled receptor signaling in the heart., Proc Natl Acad Sci U S A, 103, p. 15889, DOI: 10.1073/pnas.0607499103 63 10.1073/pnas.0607499103 false true Reference 50771245 /api/reference/50771245 64. Sysa-Shah 2016: Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways., Cardiovasc Res, 109, p. 358, DOI: 10.1093/cvr/cvv274 64 10.1093/cvr/cvv274 false true Reference 50771246 /api/reference/50771246 65. Guglin 2019: Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer., J Am Coll Cardiol, 73, p. 2859, DOI: 10.1016/j.jacc.2019.03.495 65 10.1016/j.jacc.2019.03.495 false true Reference 50771247 /api/reference/50771247 66. Monami 2013: Further data on Beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials., Curr Med Res Opin, 29, p. 369, DOI: 10.1185/03007995.2013.772505 66 10.1185/03007995.2013.772505 false true Reference 50771248 /api/reference/50771248 67. Bangalore 2011: Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials., Lancet Oncol, 12, p. 65, DOI: 10.1016/S1470-2045(10)70260-6 67 10.1016/S1470-2045(10)70260-6 false true Reference 50771249 /api/reference/50771249 68. Copland 2021: Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis., Lancet Oncol, 22, p. 558, DOI: 10.1016/S1470-2045(21)00033-4 68 10.1016/S1470-2045(21)00033-4 false true Reference 50771250 /api/reference/50771250 69. Qi 2022: Anti-Hypertensive medications and risk of colorectal cancer: a systematic review and meta-analysis., Cancer Causes Control, 33, p. 801, DOI: 10.1007/s10552-022-01570-1 69 10.1007/s10552-022-01570-1 false true Reference 50771251 /api/reference/50771251 70. Gandini 2018: Anti-Hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis., Crit Rev Oncol Hematol, 122, p. 1, DOI: 10.1016/j.critrevonc.2017.12.003 70 10.1016/j.critrevonc.2017.12.003 false true Reference 50771252 /api/reference/50771252 71. Tang 2018: Use of antihypertensive drugs and risk of malignant melanoma: a meta-analysis of observational studies., Drug Saf, 41, p. 161, DOI: 10.1007/s40264-017-0599-x 71 10.1007/s40264-017-0599-x false true Reference 50771253 /api/reference/50771253 72. Xie 2020: Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis., Aging (Albany. NY), 12, p. 1545, DOI: 10.18632/aging.102699 72 10.18632/aging.102699 false true Reference 50771254 /api/reference/50771254 73. Thiele 2015: Non-Selective Beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials., Liver Int, 35, p. 2009, DOI: 10.1111/liv.12782 73 10.1111/liv.12782 false true Reference 50771255 /api/reference/50771255 74. Weberpals 2016: Beta blockers and cancer prognosis—the role of immortal time bias: a systematic review and meta-analysis., Cancer Treat Rev, 47, p. 1, DOI: 10.1016/j.ctrv.2016.04.004 74 10.1016/j.ctrv.2016.04.004 false true Reference 50771256 /api/reference/50771256 75. Na 2018: The effects of Beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients., Onco Targets Ther, 11, p. 4913, DOI: 10.2147/OTT.S167422 75 10.2147/OTT.S167422 false true Reference 50771257 /api/reference/50771257 76. Yap 2018: Effect of Beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies., Br J Anaesth, 121, p. 45, DOI: 10.1016/j.bja.2018.03.024 76 10.1016/j.bja.2018.03.024 false true Reference 50771258 /api/reference/50771258 77. Childers 2015: β-Blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis., Clin Breast Cancer, 15, p. 426, DOI: 10.1016/j.clbc.2015.07.001 77 10.1016/j.clbc.2015.07.001 false true Reference 50771259 /api/reference/50771259 78. Raimondi 2016: Use of Beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis., Int J Cancer, 139, p. 212, DOI: 10.1002/ijc.30062 78 10.1002/ijc.30062 false true Reference 50771260 /api/reference/50771260 79. Zhong 2016: β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies., Eur J Cancer Prev, 25, p. 440, DOI: 10.1097/CEJ.0000000000000192 79 10.1097/CEJ.0000000000000192 false true Reference 50771261 /api/reference/50771261 80. Lei 2021: Beta-Blocker and survival in patients with lung cancer: a meta-analysis., PLoS One, 16, p. e0245773, DOI: 10.1371/journal.pone.0245773 80 10.1371/journal.pone.0245773 false true Reference 50771262 /api/reference/50771262 81. Vaduganathan 2019: Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy., JACC CardioOncol, 1, p. 54, DOI: 10.1016/j.jaccao.2019.08.006 81 10.1016/j.jaccao.2019.08.006 false true Reference 50771263 /api/reference/50771263 82. Cole 2015: Sympathetic nervous system regulation of the tumour microenvironment., Nat Rev Cancer, 15, p. 563, DOI: 10.1038/nrc3978 82 10.1038/nrc3978 false true Reference 50771264 /api/reference/50771264 83. George 2010: The renin–angiotensin system and cancer: old dog, new tricks., Nat Rev. Cancer, 10, p. 745, DOI: 10.1038/nrc2945 83 10.1038/nrc2945 false true Reference 50771265 /api/reference/50771265 84. Lever 1998: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?., Lancet, 352, p. 179, DOI: 10.1016/S0140-6736(98)03228-0 84 10.1016/S0140-6736(98)03228-0 false true Reference 50771266 /api/reference/50771266 85. Ino 2006: Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival., Br J Cancer, 94, p. 552, DOI: 10.1038/sj.bjc.6602961 85 10.1038/sj.bjc.6602961 false true Reference 50771267 /api/reference/50771267 86. Arrieta 2015: Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer., Tumour Biol. J, 36, p. 5627, DOI: 10.1007/s13277-015-3235-3 86 10.1007/s13277-015-3235-3 false true Reference 50771268 /api/reference/50771268 87. Nakaya 2016: Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer Xenograft model analyzed using 18F-FDG-PET/CT., Nucl Med Commun, 37, p. 139, DOI: 10.1097/MNM.0000000000000404 87 10.1097/MNM.0000000000000404 false true Reference 50771269 /api/reference/50771269 88. Fujita 2005: Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth., Carcinogenesis, 26, p. 271, DOI: 10.1093/carcin/bgh324 88 10.1093/carcin/bgh324 false true Reference 50771270 /api/reference/50771270 89. Attoub 2008: Captopril as a potential inhibitor of lung tumor growth and metastasis., Ann NY Acad Sci, 1138, p. 65, DOI: 10.1196/annals.1414.011 89 10.1196/annals.1414.011 false true Reference 50771271 /api/reference/50771271 90. Jordan 2010: Captopril and S-nitrosocaptopril as potent radiosensitizers: comparative study and underlying mechanisms., Cancer Lett, 293, p. 213, DOI: 10.1016/j.canlet.2010.01.016 90 10.1016/j.canlet.2010.01.016 false true Reference 50771272 /api/reference/50771272 91. Yang 2020: Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-ΚB/STAT3-regulated proteins., Cell Death Dis, 11, p. 477, DOI: 10.1038/s41419-020-2675-x 91 10.1038/s41419-020-2675-x false true Reference 50771273 /api/reference/50771273 92. Wysocki 2006: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice., Clin Cancer Res, 12, p. 4095, DOI: 10.1158/1078-0432.CCR-05-2489 92 10.1158/1078-0432.CCR-05-2489 false true Reference 50771274 /api/reference/50771274 93. Araújo 2015: Renin-Angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice., Urol Oncol Semin Orig Investig, 33, p. 389.e1 93 false true Reference 50771275 /api/reference/50771275 94. Brown 2004: Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines., Ann Clin Lab Sci, 34, p. 251 94 false true Reference 50771276 /api/reference/50771276 95. Rooprai 2001: Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro., Neuropathol Appl Neurobiol, 27, p. 29, DOI: 10.1046/j.0305-1846.2000.00298.x 95 10.1046/j.0305-1846.2000.00298.x false true Reference 50771277 /api/reference/50771277 96. Williams 2005: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models., Eur J Surg Oncol, 31, p. 1042, DOI: 10.1016/j.ejso.2005.04.003 96 10.1016/j.ejso.2005.04.003 false true Reference 50771278 /api/reference/50771278 97. De la Iglesia Iñigo 2009: Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents., Leuk Res, 33, p. 810, DOI: 10.1016/j.leukres.2008.09.029 97 10.1016/j.leukres.2008.09.029 false true Reference 50771279 /api/reference/50771279 98. Fendrich 2014: Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors., Endocr Relat Cancer, 21, p. 813, DOI: 10.1530/ERC-14-0175 98 10.1530/ERC-14-0175 false true Reference 50771280 /api/reference/50771280 99. Chen 2015: Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma., J Renin Angiotensin Aldosterone Syst, 16, p. 1185, DOI: 10.1177/1470320314535275 99 10.1177/1470320314535275 false true Reference 50771281 /api/reference/50771281 100. Rasha 2020: Renin angiotensin system inhibition attenuates adipocyte-breast cancer cell interactions., Exp Cell Res, 394, p. 112114, DOI: 10.1016/j.yexcr.2020.112114 100 10.1016/j.yexcr.2020.112114 false true Reference 50771282 /api/reference/50771282 101. Lu 2019: S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the Hostile bloodstream microenvironment against circulating tumor cells., Pharmacol Res, 139, p. 535, DOI: 10.1016/j.phrs.2018.10.020 101 10.1016/j.phrs.2018.10.020 false true Reference 50771283 /api/reference/50771283 102. Carl-McGrath 2007: Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread., Cancer Biol Ther, 6, p. 1218, DOI: 10.4161/cbt.6.8.4412 102 10.4161/cbt.6.8.4412 false true Reference 50771284 /api/reference/50771284 103. Smith 2016: Effects of administered cardioprotective drugs on treatment response of breast cancer cells., Anticancer Res, 36, p. 87 103 false true Reference 50771285 /api/reference/50771285 104. Okazaki 2014: The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer., Cancer Lett, 355, p. 46, DOI: 10.1016/j.canlet.2014.09.019 104 10.1016/j.canlet.2014.09.019 false true Reference 50771286 /api/reference/50771286 105. Takagi 2021: The angiotensin II receptor blocker losartan sensitizes human liver cancer cells to lenvatinib-mediated cytostatic and angiostatic effects., Cells, 10, p. 575, DOI: 10.3390/cells10030575 105 10.3390/cells10030575 false true Reference 50771287 /api/reference/50771287 106. Mainetti 2020: Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models., Oncotarget, 11, p. 3048, DOI: 10.18632/oncotarget.27694 106 10.18632/oncotarget.27694 false true Reference 50771288 /api/reference/50771288 107. Li 2021: Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model., Radiat Oncol, 16, p. 48, DOI: 10.1186/s13014-021-01775-9 107 10.1186/s13014-021-01775-9 false true Reference 50771289 /api/reference/50771289 108. Regan 2019: The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment., J Immunol, 202, p. 3087, DOI: 10.4049/jimmunol.1800619 108 10.4049/jimmunol.1800619 false true Reference 50771290 /api/reference/50771290 109. Cai 2021: Candesartan treatment enhances liposome penetration and anti-tumor effect via depletion of tumor stroma and normalization of tumor vessel., Drug Deliv Transl Res, 11, p. 1186, DOI: 10.1007/s13346-020-00842-0 109 10.1007/s13346-020-00842-0 false true Reference 50771291 /api/reference/50771291 110. Ruderman 2018: Early increase in blood supply (EIBS) is associated with tumor risk in the azoxymethane model of colon cancer., BMC Cancer, 18, p. 814, DOI: 10.1186/s12885-018-4709-7 110 10.1186/s12885-018-4709-7 false true Reference 50771292 /api/reference/50771292 111. Hashemzehi 2021: Angiotensin receptor blocker losartan inhibits tumor growth of colorectal cancer., EXCLI J, 20, p. 506 111 false true Reference 50771293 /api/reference/50771293 112. Oh 2016: Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis., Biochim Biophys Acta, 1863, p. 1071, DOI: 10.1016/j.bbamcr.2016.03.010 112 10.1016/j.bbamcr.2016.03.010 false true Reference 50771294 /api/reference/50771294 113. Saber 2018: Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B., Toxicol Lett, 295, p. 32, DOI: 10.1016/j.toxlet.2018.05.036 113 10.1016/j.toxlet.2018.05.036 false true Reference 50771295 /api/reference/50771295 114. Rhodes 2009: AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist., Proc Natl Acad Sci U S A, 106, p. 10284, DOI: 10.1073/pnas.0900351106 114 10.1073/pnas.0900351106 false true Reference 50771296 /api/reference/50771296 115. Xia 2018: Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with PH sensitive peptides by inhibition of collagen in breast cancer., Pharm Dev Technol, 23, p. 13, DOI: 10.1080/10837450.2016.1265553 115 10.1080/10837450.2016.1265553 false true Reference 50771297 /api/reference/50771297 116. Hu 2017: Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer., Biomaterials, 144, p. 60, DOI: 10.1016/j.biomaterials.2017.08.009 116 10.1016/j.biomaterials.2017.08.009 false true Reference 50771298 /api/reference/50771298 117. Redondo-Müller 2008: Anti-Cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor., Endocr Relat Cancer, 15, p. 277, DOI: 10.1677/ERC-07-0068 117 10.1677/ERC-07-0068 false true Reference 50771299 /api/reference/50771299 118. Kosugi 2006: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a Xenograft model of bladder cancer., Clin Cancer Res, 12, p. 2888, DOI: 10.1158/1078-0432.CCR-05-2213 118 10.1158/1078-0432.CCR-05-2213 false true Reference 50771300 /api/reference/50771300 119. Kosugi 2007: Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a Xenograft model of human bladder cancer., Hum Cell, 20, p. 1, DOI: 10.1111/j.1749-0774.2007.00025.x 119 10.1111/j.1749-0774.2007.00025.x false true Reference 50771301 /api/reference/50771301 120. Wilisch-Neumann 2014: Re-Evaluation of cytostatic therapies for meningiomas in vitro., J Cancer Res Clin Oncol, 140, p. 1343, DOI: 10.1007/s00432-014-1683-6 120 10.1007/s00432-014-1683-6 false true Reference 50771302 /api/reference/50771302 121. Funao 2009: Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma., Mol Med Rep, 2, p. 193 121 false true Reference 50771303 /api/reference/50771303 122. Olschewski 2018: The angiotensin II type 1 receptor antagonist losartan affects NHE1-dependent melanoma cell behavior., Cell Physiol Biochem, 45, p. 2560, DOI: 10.1159/000488274 122 10.1159/000488274 false true Reference 50771304 /api/reference/50771304 123. Martínez 2018: Interaction of Zn with losartan. Activation of intrinsic apoptotic signaling pathway in lung cancer cells and effects on alkaline and acid phosphatases., Biol Trace Elem Res, 186, p. 413, DOI: 10.1007/s12011-018-1334-x 123 10.1007/s12011-018-1334-x false true Reference 50771305 /api/reference/50771305 124. Fujihara 2017: The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/MTOR pathway in vitro and in vivo., Oncotarget, 8, p. 8536, DOI: 10.18632/oncotarget.14345 124 10.18632/oncotarget.14345 false true Reference 50771306 /api/reference/50771306 125. Oura 2017: Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest., Oncol Rep, 38, p. 2825, DOI: 10.3892/or.2017.5977 125 10.3892/or.2017.5977 false true Reference 50771307 /api/reference/50771307 126. Kobara 2020: Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro., Mol Med Rep, 22, p. 1063, DOI: 10.3892/mmr.2020.11144 126 10.3892/mmr.2020.11144 false true Reference 50771308 /api/reference/50771308 127. Woo 2017: Angiotensin II receptor blockers induce autophagy in prostate cancer cells., Oncol Lett, 13, p. 3579, DOI: 10.3892/ol.2017.5872 127 10.3892/ol.2017.5872 false true Reference 50771309 /api/reference/50771309 128. Leung 2013: Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation., J Exp Med, 210, p. 2675, DOI: 10.1084/jem.20122292 128 10.1084/jem.20122292 false true Reference 50771310 /api/reference/50771310 129. Shahar 2014: A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug spironolactone impairs cancer cell survival by inhibiting homology directed repair., Nucleic Acids Res, 42, p. 5689, DOI: 10.1093/nar/gku217 129 10.1093/nar/gku217 false true Reference 50771311 /api/reference/50771311 130. Gold 2019: Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response., Oncogene, 38, p. 3103, DOI: 10.1038/s41388-018-0654-9 130 10.1038/s41388-018-0654-9 false true Reference 50771312 /api/reference/50771312 131. Kaji 2010: Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice., Hepatol Res, 40, p. 540, DOI: 10.1111/j.1872-034X.2010.00636.x 131 10.1111/j.1872-034X.2010.00636.x false true Reference 50771313 /api/reference/50771313 132. Feldman 2016: Aldosterone mediates metastatic spread of renal cancer via the G protein-coupled estrogen receptor (GPER)., FASEB J, 30, p. 2086, DOI: 10.1096/fj.15-275552 132 10.1096/fj.15-275552 false true Reference 50771314 /api/reference/50771314 133. Isobe 2010: Aldosterone stimulates the proliferation of uterine leiomyoma cells., Gynecol Endocrinol, 26, p. 372, DOI: 10.3109/09513590903511521 133 10.3109/09513590903511521 false true Reference 50771315 /api/reference/50771315 134. Lee 2011: Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines., Korean J Hepatol, 17, p. 213, DOI: 10.3350/kjhep.2011.17.3.213 134 10.3350/kjhep.2011.17.3.213 false true Reference 50771316 /api/reference/50771316 135. King 2014: Evidence for aldosterone-dependent growth of renal cell carcinoma., Int J Exp Pathol, 95, p. 244, DOI: 10.1111/iep.12074 135 10.1111/iep.12074 false true Reference 50771317 /api/reference/50771317 136. Fidrus 2021: Inhibitors of nucleotide excision repair decrease UVB-induced mutagenesis-an in vitro study., Int J Mol Sci, 22, p. 1638, DOI: 10.3390/ijms22041638 136 10.3390/ijms22041638 false true Reference 50771318 /api/reference/50771318 137. Sanomachi 2019: Spironolactone, a classic potassium-sparing diuretic, reduces survivin expression and chemosensitizes cancer cells to non-DNA-damaging anticancer drugs., Cancers (Basel), 11, p. 1550, DOI: 10.3390/cancers11101550 137 10.3390/cancers11101550 false true Reference 50771319 /api/reference/50771319 138. Nogami 2016: Estradiol and corticosterone stimulate the proliferation of a GH cell line, MtT/S: proliferation of growth hormone cells., Growth Horm IGF Res, 29, p. 33, DOI: 10.1016/j.ghir.2016.03.006 138 10.1016/j.ghir.2016.03.006 false true Reference 50771320 /api/reference/50771320 139. Aldaz 2021: Novel insights into the role of the mineralocorticoid receptor in human glioblastoma., Int J Mol Sci, 22, p. 11656, DOI: 10.3390/ijms222111656 139 10.3390/ijms222111656 false true Reference 50771321 /api/reference/50771321 140. Sipahi 2010: Angiotensin-Receptor blockade and risk of cancer: meta-analysis of randomised controlled trials., Lancet Oncol, 11, p. 627, DOI: 10.1016/S1470-2045(10)70106-6 140 10.1016/S1470-2045(10)70106-6 false true Reference 50771322 /api/reference/50771322 141. Pasternak 2011: Use of angiotensin receptor blockers and the risk of cancer., Circulation, 123, p. 1729, DOI: 10.1161/CIRCULATIONAHA.110.007336 141 10.1161/CIRCULATIONAHA.110.007336 false true Reference 50771323 /api/reference/50771323 142. Datzmann 2019: Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer., Eur J Intern Med, 64, p. 1, DOI: 10.1016/j.ejim.2019.04.019 142 10.1016/j.ejim.2019.04.019 false true Reference 50771324 /api/reference/50771324 143. Shen 2016: Renin-Angiotensin system blockade for the risk of cancer and death., J Renin Angiotensin Aldosterone Syst, 17, DOI: 10.1177/1470320316656679 143 10.1177/1470320316656679 false true Reference 50771325 /api/reference/50771325 144. Sipahi 2011: Meta-Analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk., Am J Cardiol, 108, p. 294, DOI: 10.1016/j.amjcard.2011.03.038 144 10.1016/j.amjcard.2011.03.038 false true Reference 50771326 /api/reference/50771326 145. Coleman 2008: Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials., J Hypertens, 26, p. 622, DOI: 10.1097/HJH.0b013e3282f3ef5e 145 10.1097/HJH.0b013e3282f3ef5e false true Reference 50771327 /api/reference/50771327 146. Cao 2018: Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies., BMC Urol, 18, p. 17, DOI: 10.1186/s12894-018-0318-7 146 10.1186/s12894-018-0318-7 false true Reference 50771328 /api/reference/50771328 147. Batais 2021: Angiotensin converting enzyme inhibitors and risk of lung cancer: a systematic review and meta-analysis., Medicine (Baltimore), 100, p. e25714, DOI: 10.1097/MD.0000000000025714 147 10.1097/MD.0000000000025714 false true Reference 50771329 /api/reference/50771329 148. Yoon 2011: Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies., CMAJ, 183, p. E1073, DOI: 10.1503/cmaj.101497 148 10.1503/cmaj.101497 false true Reference 50771330 /api/reference/50771330 149. Dai 2015: Angiotensin-Converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis., Cancer Causes Control, 26, p. 1245, DOI: 10.1007/s10552-015-0617-1 149 10.1007/s10552-015-0617-1 false true Reference 50771331 /api/reference/50771331 150. Mao 2016: Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?., Oncotarget, 7, p. 6765, DOI: 10.18632/oncotarget.6837 150 10.18632/oncotarget.6837 false true Reference 50771332 /api/reference/50771332 151. Bommareddy 2022: Association of spironolactone use with risk of cancer: a systematic review and meta-analysis., JAMA Dermatol, 158, p. 275, DOI: 10.1001/jamadermatol.2021.5866 151 10.1001/jamadermatol.2021.5866 false true Reference 50771333 /api/reference/50771333 152. Zhou 2020: The renin-angiotensin system blockers and survival in digestive system malignancies: a systematic review and meta-analysis., Medicine (Baltimore), 99, p. e19075, DOI: 10.1097/MD.0000000000019075 152 10.1097/MD.0000000000019075 false true Reference 50771334 /api/reference/50771334 153. Sun 2017: Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?., Med, 96, p. e6394, DOI: 10.1097/MD.0000000000006394 153 10.1097/MD.0000000000006394 false true Reference 50771335 /api/reference/50771335 154. Chen 2020: Renin-Angiotensin system inhibitor use and colorectal cancer risk and mortality: a dose-response meta analysis., J Renin Angiotensin Aldosterone Syst, 21, DOI: 10.1177/1470320319895646 154 10.1177/1470320319895646 false true Reference 50771336 /api/reference/50771336 155. Asgharzadeh 2020: Angiotensin-Converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: a meta-analysis., Life Sci, 242, p. 117181, DOI: 10.1016/j.lfs.2019.117181 155 10.1016/j.lfs.2019.117181 false true Reference 50771337 /api/reference/50771337 156. Song 2017: The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis., Eur J Cancer Prev, 26, p. 78, DOI: 10.1097/CEJ.0000000000000269 156 10.1097/CEJ.0000000000000269 false true Reference 50771338 /api/reference/50771338 157. Zhao 2016: Angiotensin II receptor blockers and cancer risk: a meta-analysis of randomized controlled trials., Medicine (Baltimore), 95, p. e3600, DOI: 10.1097/MD.0000000000003600 157 10.1097/MD.0000000000003600 false true Reference 50771339 /api/reference/50771339 158. Myhre 2019: B-Type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial., J Am Coll Cardiol, 73, p. 1264, DOI: 10.1016/j.jacc.2019.01.018 158 10.1016/j.jacc.2019.01.018 false true Reference 50771340 /api/reference/50771340 159. Murphy 2021: Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction., JACC Heart Fail, 9, p. 127, DOI: 10.1016/j.jchf.2020.09.013 159 10.1016/j.jchf.2020.09.013 false true Reference 50771341 /api/reference/50771341 160. Desai 2015: Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients., Eur Heart J, 36, p. 1990, DOI: 10.1093/eurheartj/ehv186 160 10.1093/eurheartj/ehv186 false true Reference 50771342 /api/reference/50771342 161. Stolfo 2023: Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction., Eur Heart J Cardiovasc Pharmacother, 9, p. 526, DOI: 10.1093/ehjcvp/pvad036 161 10.1093/ehjcvp/pvad036 false true Reference 50771343 /api/reference/50771343 162. Vesely 2003: Four peptides decrease the number of human pancreatic adenocarcinoma cells., Eur J Clin Invest, 33, p. 998, DOI: 10.1046/j.1365-2362.2003.01262.x 162 10.1046/j.1365-2362.2003.01262.x false true Reference 50771344 /api/reference/50771344 163. Vesely 2006: Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells., Cancer Lett, 233, p. 226, DOI: 10.1016/j.canlet.2005.03.024 163 10.1016/j.canlet.2005.03.024 false true Reference 50771345 /api/reference/50771345 164. Vesely 2005: Five cardiac hormones decrease the number of human small-cell lung cancer cells., Eur J Clin Invest, 35, p. 388, DOI: 10.1111/j.1365-2362.2005.01501.x 164 10.1111/j.1365-2362.2005.01501.x false true Reference 50771346 /api/reference/50771346 165. Vesely 2004: Novel therapeutic approach for cancer using four cardiovascular hormones., Eur J Clin Invest, 34, p. 674, DOI: 10.1111/j.1365-2362.2004.01402.x 165 10.1111/j.1365-2362.2004.01402.x false true Reference 50771347 /api/reference/50771347 166. Ohsaki 1999: Human small cell lung cancer cells produce brain natriuretic peptide., Oncology, 56, p. 155, DOI: 10.1159/000011957 166 10.1159/000011957 false true Reference 50771348 /api/reference/50771348 167. Wigle 1995: ANP secretion from small cell lung cancer cell lines: a potential model of ANP release., Am J Physiol Circ Physiol, 268, p. H1869, DOI: 10.1152/ajpheart.1995.268.5.H1869 167 10.1152/ajpheart.1995.268.5.H1869 false true Reference 50771349 /api/reference/50771349 168. Pavo 2020: Neprilysin as a biomarker: challenges and opportunities., Card Fail Rev, 6, p. e23, DOI: 10.15420/cfr.2019.21 168 10.15420/cfr.2019.21 false true Reference 50771350 /api/reference/50771350 169. Scafoglio 2015: Functional expression of sodium-glucose transporters in cancer., Proc Natl Acad Sci U S A, 112, p. E4111, DOI: 10.1073/pnas.1511698112 169 10.1073/pnas.1511698112 false true Reference 50771351 /api/reference/50771351 170. Dutka 2022: SGLT-2 Inhibitors in cancer treatment— mechanisms of action and emerging new perspectives., Cancers (Basel), 14, p. 5811, DOI: 10.3390/cancers14235811 170 10.3390/cancers14235811 false true Reference 50771352 /api/reference/50771352 171. Zhou 2020: Sodium-Glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/MTOR pathway., Biomed Pharmacother, 132, p. 110821, DOI: 10.1016/j.biopha.2020.110821 171 10.1016/j.biopha.2020.110821 false true Reference 50771353 /api/reference/50771353 172. Nasiri 2019: SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia., Cancer Metab, 7, p. 10, DOI: 10.1186/s40170-019-0203-1 172 10.1186/s40170-019-0203-1 false true Reference 50771354 /api/reference/50771354 173. Villani 2016: The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial Complex-I supported respiration., Mol Metab, 5, p. 1048, DOI: 10.1016/j.molmet.2016.08.014 173 10.1016/j.molmet.2016.08.014 false true Reference 50771355 /api/reference/50771355 174. Kaji 2018: Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake., Int J Cancer, 142, p. 1712, DOI: 10.1002/ijc.31193 174 10.1002/ijc.31193 false true Reference 50771356 /api/reference/50771356 175. Kabel 2021: Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: the interaction between nitric oxide, transforming growth factor-Beta 1, autophagy, and apoptosis., Fundam Clin Pharmacol, 35, p. 968, DOI: 10.1111/fcp.12661 175 10.1111/fcp.12661 false true Reference 50771357 /api/reference/50771357 176. Xie 2020: An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells., Cancer Lett, 495, p. 200, DOI: 10.1016/j.canlet.2020.09.005 176 10.1016/j.canlet.2020.09.005 false true Reference 50771358 /api/reference/50771358 177. Ren 2021: SGLT2 promotes pancreatic cancer progression by activating the hippo signaling pathway via the HnRNPK-YAP1 axis., Cancer Lett, 519, p. 277, DOI: 10.1016/j.canlet.2021.07.035 177 10.1016/j.canlet.2021.07.035 false true Reference 50771359 /api/reference/50771359 178. Korfhage 2022: Canagliflozin increases intestinal adenoma burden in female ApcMin/+ mice., J Gerontol A Biol Sci Med Sci, 77, p. 215, DOI: 10.1093/gerona/glab254 178 10.1093/gerona/glab254 false true Reference 50771360 /api/reference/50771360 179. Shoda 2022: Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK., Cell Mol Neurobiol, 43, p. 879, DOI: 10.1007/s10571-022-01221-8 179 10.1007/s10571-022-01221-8 false true Reference 50771361 /api/reference/50771361 180. Xu 2020: Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A., Int J Oncol, 57, p. 1223 180 false true Reference 50771362 /api/reference/50771362 181. Nakano 2020: Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (IMPAQT)., PLoS One, 15, p. e0232283, DOI: 10.1371/journal.pone.0232283 181 10.1371/journal.pone.0232283 false true Reference 50771363 /api/reference/50771363 182. Papadopoli 2021: Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin., Neoplasia, 23, p. 391, DOI: 10.1016/j.neo.2021.02.003 182 10.1016/j.neo.2021.02.003 false true Reference 50771364 /api/reference/50771364 183. Yamamoto 2021: Sodium-Glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro., Diabetol Int, 12, p. 389, DOI: 10.1007/s13340-021-00494-6 183 10.1007/s13340-021-00494-6 false true Reference 50771365 /api/reference/50771365 184. Wang 2019: Trilobatin, a novel SGLT1/2 inhibitor, selectively induces the proliferation of human hepatoblastoma cells., Molecules, 24, p. 3390, DOI: 10.3390/molecules24183390 184 10.3390/molecules24183390 false true Reference 50771366 /api/reference/50771366 185. Hung 2019: Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation., Cell Death Dis, 10, p. 420, DOI: 10.1038/s41419-019-1646-6 185 10.1038/s41419-019-1646-6 false true Reference 50771367 /api/reference/50771367 186. Madonna 2022: Sodium-Glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: a potential rescue strategy., Vascul Pharmacol, 142, p. 106949, DOI: 10.1016/j.vph.2021.106949 186 10.1016/j.vph.2021.106949 false true Reference 50771368 /api/reference/50771368 187. Lin 2014: A review on the relationship between SGLT2 inhibitors and cancer., Int J Endocrinol, 2014, p. 719578, DOI: 10.1155/2014/719578 187 10.1155/2014/719578 false true Reference 50771369 /api/reference/50771369 188. Benedetti 2022: Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials., Pharmacol Res, 175, p. 106039, DOI: 10.1016/j.phrs.2021.106039 188 10.1016/j.phrs.2021.106039 false true Reference 50771370 /api/reference/50771370 189. Shi 2021: SGLT-2i and risk of malignancy in type 2 diabetes: a meta-analysis of randomized controlled trials., Front Public Heal, 9, p. 668368, DOI: 10.3389/fpubh.2021.668368 189 10.3389/fpubh.2021.668368 false true Reference 50771371 /api/reference/50771371 190. Tang 2017: SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials., Diabetologia, 60, p. 1862, DOI: 10.1007/s00125-017-4370-8 190 10.1007/s00125-017-4370-8 false true Reference 50771372 /api/reference/50771372 191. Dicembrini 2019: Sodium-Glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials., Diabetes Obes Metab, 21, p. 1871, DOI: 10.1111/dom.13745 191 10.1111/dom.13745 false true Reference 50771373 /api/reference/50771373 192. Cui 2022: Antidiabetic medications and the risk of prostate cancer in patients with diabetes Mellitus: a systematic review and meta-analysis., Pharmacol Res, 177, p. 106094, DOI: 10.1016/j.phrs.2022.106094 192 10.1016/j.phrs.2022.106094 false true Reference 50771374 /api/reference/50771374 193. Tang 2018: Meta-Analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes., Diabetes Obes Metab, 20, p. 2919, DOI: 10.1111/dom.13474 193 10.1111/dom.13474 false true Reference 50771375 /api/reference/50771375 194. Chou 2021: Inhibitory effects of digoxin and digitoxin on cell growth in human ovarian cancer cell line SKOV-3., Integr Cancer Ther, 20, DOI: 10.1177/15347354211002662 194 10.1177/15347354211002662 false true Reference 50771376 /api/reference/50771376 195. Hou 2020: Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro., Gastroenterol Rep, 8, p. 465, DOI: 10.1093/gastro/goaa076 195 10.1093/gastro/goaa076 false true Reference 50771377 /api/reference/50771377 196. Deng 2019: Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer., Cancer Biol Ther, 20, p. 52, DOI: 10.1080/15384047.2018.1504723 196 10.1080/15384047.2018.1504723 false true Reference 50771378 /api/reference/50771378 197. Joseph 2015: Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis., Cancer Lett, 359, p. 107, DOI: 10.1016/j.canlet.2015.01.010 197 10.1016/j.canlet.2015.01.010 false true Reference 50771379 /api/reference/50771379 198. Zhang 2017: The combination of digoxin and GSK2606414 exerts synergistic anticancer activity against leukemia in vitro and in vivo., BioFactors, 43, p. 812, DOI: 10.1002/biof.1380 198 10.1002/biof.1380 false true Reference 50771380 /api/reference/50771380 199. Wang 2009: Cardiac glycosides inhibit P53 synthesis by a mechanism relieved by src or MAPK inhibition., Cancer Res, 69, p. 6556, DOI: 10.1158/0008-5472.CAN-09-0891 199 10.1158/0008-5472.CAN-09-0891 false true Reference 50771381 /api/reference/50771381 200. Wang 2020: Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of Adriamycin., Front Pharmacol, 11, p. 186, DOI: 10.3389/fphar.2020.00186 200 10.3389/fphar.2020.00186 false true Reference 50771382 /api/reference/50771382 201. Glass 2017: Differential response to exercise in claudin-low breast cancer., Oncotarget, 8, p. 100989, DOI: 10.18632/oncotarget.21054 201 10.18632/oncotarget.21054 false true Reference 50771383 /api/reference/50771383 202. Crezee 2021: Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer., Cell Oncol, 44, p. 611, DOI: 10.1007/s13402-021-00588-y 202 10.1007/s13402-021-00588-y false true Reference 50771384 /api/reference/50771384 203. Beheshti Zavareh 2008: Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function., Cancer Res, 68, p. 6688, DOI: 10.1158/0008-5472.CAN-07-6833 203 10.1158/0008-5472.CAN-07-6833 false true Reference 50771385 /api/reference/50771385 204. Ahern 2014: Digoxin use and risk of invasive breast cancer: evidence from the nurses’ health study and meta-analysis., Breast Cancer Res Treat, 144, p. 427, DOI: 10.1007/s10549-014-2886-x 204 10.1007/s10549-014-2886-x false true Reference 50771386 /api/reference/50771386 205. Osman 2017: Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies., PLoS One, 12, p. e0178611, DOI: 10.1371/journal.pone.0178611 205 10.1371/journal.pone.0178611 false true Reference 50771387 /api/reference/50771387 206. Panet 2000: Overexpression of the Na+/K+/Cl− cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts., J Cell Physiol, 182, p. 109, DOI: 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A 206 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A false true Reference 50771388 /api/reference/50771388 207. Iwamoto 2004: Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation., Am J Physiol Cell Mol Physiol, 287, p. L510, DOI: 10.1152/ajplung.00021.2004 207 10.1152/ajplung.00021.2004 false true Reference 50771389 /api/reference/50771389 208. Shiozaki 2014: Role of the na +/K +/2Cl− cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma., World J Gastroenterol, 20, p. 6844, DOI: 10.3748/wjg.v20.i22.6844 208 10.3748/wjg.v20.i22.6844 false true Reference 50771390 /api/reference/50771390 209. Liu 2019: Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study., BMC Cancer, 19, p. 1017, DOI: 10.1186/s12885-019-6242-8 209 10.1186/s12885-019-6242-8 false true Reference 50771391 /api/reference/50771391 210. Shin 2019: Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies., J Clin Med Res, 11, p. 247, DOI: 10.14740/jocmr3744 210 10.14740/jocmr3744 false true Reference 50771392 /api/reference/50771392 211. Heisel 2023: The use of specific antihypertensive medication and skin cancer risk: a systematic review of the literature and meta-analysis., Vascul Pharmacol, 150, p. 107173, DOI: 10.1016/j.vph.2023.107173 211 10.1016/j.vph.2023.107173 false true Reference 50771393 /api/reference/50771393 212. Sayour 2023: Cardioprotective efficacy of limb remote ischaemic preconditioning in rats: discrepancy between a meta-analysis and a three-centre in vivo study., Cardiovasc Res, 119, p. 1336, DOI: 10.1093/cvr/cvad024 212 10.1093/cvr/cvad024 false true Reference 50771394 /api/reference/50771394 213. Begley 2015: Reproducibility in science., Circ Res, 116, p. 116, DOI: 10.1161/CIRCRESAHA.114.303819 213 10.1161/CIRCRESAHA.114.303819 false true Reference 50771395 /api/reference/50771395 214. Avraham 2020: Early cardiac remodeling promotes tumor growth and metastasis., Circulation, 142, p. 670, DOI: 10.1161/CIRCULATIONAHA.120.046471 214 10.1161/CIRCULATIONAHA.120.046471 false true Reference 50771396 /api/reference/50771396 215. Meijers 2018: Heart failure stimulates tumor growth by circulating factors., Circulation, 138, p. 678, DOI: 10.1161/CIRCULATIONAHA.117.030816 215 10.1161/CIRCULATIONAHA.117.030816 false true Reference 50771397 /api/reference/50771397 216. Koelwyn 2020: Myocardial infarction accelerates breast cancer via innate immune reprogramming., Nat Med, 26, p. 1452, DOI: 10.1038/s41591-020-0964-7 216 10.1038/s41591-020-0964-7 false true Reference 50771398 /api/reference/50771398 217. de Wit 2023: Pressure overload–induced cardiac hypertrophy stimulates tumor growth in tumor-prone ApcMin mice., Circ Heart Fail, 0, p. e010740 217 false true Reference 50771399 /api/reference/50771399 218. Sayour 2023: Droplet digital PCR is a novel screening method identifying potential cardiac G-protein-coupled receptors as candidate pharmacological targets in a rat model of pressure-overload-induced cardiac dysfunction., Int J Mol Sci, 24, p. 13826, DOI: 10.3390/ijms241813826 218 10.3390/ijms241813826 false true Reference 50771400 /api/reference/50771400 219. Dobbin 2023: Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials., Eur J Heart Fail, 25, p. 488, DOI: 10.1002/ejhf.2818 219 10.1002/ejhf.2818 false true Reference 50771401 /api/reference/50771401 220. Tini 2020: Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis., J Am Heart Assoc, 9, p. e016309, DOI: 10.1161/JAHA.119.016309 220 10.1161/JAHA.119.016309 false true Reference 50771402 /api/reference/50771402 221. Lehmann 2023: Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis., Circulation, 148, p. 473, DOI: 10.1161/CIRCULATIONAHA.123.062405 221 10.1161/CIRCULATIONAHA.123.062405 false true Reference 50771403 /api/reference/50771403 222. Rathore 2002: Sex-Based differences in the effect of digoxin for the treatment of heart failure., N Engl J Med, 347, p. 1403, DOI: 10.1056/NEJMoa021266 222 10.1056/NEJMoa021266 false true Reference 50771404 /api/reference/50771404 223. Davide 2019: Sex-Based differences in heart failure across the ejection fraction Spectrum., JACC Heart Fail, 7, p. 505, DOI: 10.1016/j.jchf.2019.03.011 223 10.1016/j.jchf.2019.03.011 false true Reference 50771405 /api/reference/50771405 224. Ridker 2017: Antiinflammatory therapy with canakinumab for atherosclerotic disease., N Engl J Med, 377, p. 1119, DOI: 10.1056/NEJMoa1707914 224 10.1056/NEJMoa1707914 false true Reference 50771406 /api/reference/50771406 225. Everett 2019: Anti-Inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure., Circulation, 139, p. 1289, DOI: 10.1161/CIRCULATIONAHA.118.038010 225 10.1161/CIRCULATIONAHA.118.038010 false true Reference 50771407 /api/reference/50771407 226. Ridker 2017: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial., Lancet, 390, p. 1833, DOI: 10.1016/S0140-6736(17)32247-X 226 10.1016/S0140-6736(17)32247-X false true /api/publication/34724783 Sayour Nabil V et al. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. (2024) EUROPEAN HEART JOURNAL 0195-668X 1522-9645 45 14 1224-1240<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <a href="/gui2/?type=authors&mode=browse&sel=10074459" target="_blank">Sayour Nabil V (Sayour Viktor Nabil farmakológia) </a> SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/AOK/I/FFI/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; SE/AOK/I/FFI/MTA-SE Momentum Kardio-Onkológia és Kardioimmunológia Kutatócsoport ;    <a href="/gui2/?type=authors&mode=browse&sel=10077413" target="_blank">Paál Ágnes M (Paál Ágnes farmakológia) </a> SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet ;    Ameri Pietro ;    Meijers Wouter C ;    Minotti Giorgio ;    Andreadou Ioanna ;    Lombardo Antonella ;    Camilli Massimiliano ;    Drexel Heinz ;    Grove Erik Lerkevang ;    Dan Gheorghe Andrei ;    Ivanescu Andreea ;    Semb Anne Grete ;    Savarese Gianluigi ;    Dobrev Dobromir ;    Crea Filippo ;    Kaski Juan-Carlos ;    de Boer Rudolf A ;    <a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter** (Ferdinandy Péter Farmakológia, molekuláris medicina) </a> SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/AOK/I/FFI/MTA-SE Rendszerfarmakológiai Kutatócsoport ;    <a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V ✉ (Varga Zoltán kardiovaszkuláris kutatás) </a> SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/AOK/I/FFI/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; SE/AOK/I/FFI/MTA-SE Momentum Kardio-Onkológia és Kardioimmunológia Kutatócsoport </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34724783" target="_blank">Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence</a></div> <div> EUROPEAN HEART JOURNAL (<a target="_blank" href="https://portal.issn.org/resource/ISSN/0195-668X">0195-668X</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1522-9645">1522-9645</a>): 45 14 pp 1224-1240 (2024) </div> <div class="pub-footer"> Nyelv: Angol | <a style="color:blue" title="10.1093/eurheartj/ehae105" target="_blank" href="https://doi.org/10.1093/eurheartj/ehae105"> DOI </a> <a style="color:blue" title="001178569200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001178569200001"> WoS </a> <a style="color:blue" title="85188432275" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85188432275"> Scopus </a> <a style="color:blue" title="38441940" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38441940&dopt=Abstract"> PubMed </a> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine   SJR indikátor: D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> Nyilvános idéző összesen: 33 | Független: 22 | Függő: 11 | Nem jelölt: 0 | WoS jelölt: 33 | Scopus jelölt: 31 | WoS/Scopus jelölt: 33 | DOI jelölt: 33 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34724783&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 10 </a> </div> <div class="mtid">Közlemény: 34724783 | Egyeztetett Forrás Idéző | Folyóiratcikk ( Összefoglaló cikk ) | Tudományos | kézi felvitel </div> <div class="funder"> HCEMM(739593) Támogató: Horizon 2020, (LP-2021-38) Támogató: Hungarian Academy of Sciences, National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751), Tématerületi Kiválósági Program(2020-4.1.1.-TKP2020), (2020-1.1.5-GYORSÍTÓSÁV-2021-00011), (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium, (TKP/ITM/NKFIH), Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH, Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP </div> <div class="lastModified">Utolsó módosítás: 2025.05.16. 13:10 Gere Tamásné (SE_KK_Admin5_GT, admin) </div> <div class="lockedBy">Központi kezelésű 2025.06.05. 01:11 Lévayné Deseő Katalin (MTMT Központi admin) </div> </div></div>